Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharmaceutical company Amarin
So what: In a late-stage clinical trial, Amarin's lead product candidate, AMR101, was effective at reducing triglycerides without increasing LDL cholesterol, or "bad cholesterol," after 12 weeks. Lovaza -- GlaxoSmithKline's
Now what: Amarin seems like an interesting situation for speculative investors. AMR101 continues to display clear benefits over competing triglyceride drugs, making it an increasingly tempting takeover target. It's hard to believe, but even with today's 80%-plus surge, Amarin might still be a steal for a patent cliff-facing drug giant.
Interested in more info on Amarin? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Glaxo is a Motley Fool Global Gains selection, and the Fool owns shares of it. Try any of our Foolish newsletter services free for 30 days.